International Clinical Trial: A Single-Center, Open-Label, Randomized, Single-Dose, Four-Period, Two-Sequence, Fully Replicate Crossover Trial to Assess the Bioequivalence of Test Product Sacubitril and Valsartan Tablets (Strength: Sacubitril 97 mg/ Valsartan 103 mg) and Reference Product (ENTRESTO(R)) (Strength: Sacubitril 97 mg/ Valsartan 103 mg) in Healthy Adult Participants under Fed Conditions

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127804) titled 'A Single-Center, Open-Label, Randomized, Single-Dose, Four-Period, Two-Sequence, Fully Replicate Crossover Trial to Assess the Bioequivalence of Test Product Sacubitril and Valsartan Tablets (Strength: Sacubitril 97 mg/ Valsartan 103 mg) and Reference Product (ENTRESTO(R)) (Strength: Sacubitril 97 mg/ Valsartan 103 mg) in Healthy Adult Participants under Fed Conditions' on July 8.

Study Type: Interventional study

Study Design: Cross-over

Primary Sponsor: Hangzhou Combak Hospital

Condition: Heart failure

Intervention: Sequence Group 1:Sacubitril and Valsartan Tablets,Strength:Sacubitril 97 mg/ Valsartan 103...